Rockville, MD and Irvine, CA — January 18, 2022 – Boustead Securities, LLC (“Boustead”) client Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), announces that Chairman and Chief Executive Officer, Anatoly Dritschilo, M.D., CEO, and other Shuttle Pharmaceuticals and Boustead team members, including Boustead's CEO Keith Moore, will ring the Nasdaq opening bell on Wednesday, January 18, 2023.
"Shuttle is excited to open the Nasdaq this morning to commemorate our recent IPO and the advancement of our lead product candidate aimed at improving the outcomes of cancer treatment through radiation therapy while reducing its side effects," commented Shuttle Pharma's Chairman and CEO, Anatoly Dritschilo, M.D. "We are excited about developing our platform of radiation sensitizers and the future opportunities it will bring as we work through our milestones and look to deliver innovative new treatments to thousands of patients who currently lack effective therapies."
Boustead’s Adam Carles also joined the celebration. The Opening Bell ceremony will be broadcast live starting at 9:15 a.m. Eastern Time from the Nasdaq MarketSite Tower in New York City, New York. To view the broadcast, please visit: https://www.nasdaq.com/marketsite/bell-ringing-ceremony.
About TCG GreenChem
TCG GreenChem, Inc., based in Princeton South, NJ and Richmond, VA, brings the experience, technological expertise and know-how, which is required to meet the objectives of drug development and manufacturing. The TCG GreenChem Research and Development Center at Princeton South has state of the art process research labs, analytical capabilities, and cGMP Kilo Laboratories to manufacture and release API.
TCG GreenChem, Inc. in the United States is a subsidiary of TCG Lifesciences Pvt Ltd. TCG Lifesciences is a private limited firm (formerly "Chembiotek Research International"), a leading global Contract Research and Manufacturing Services (CRAMS) and CDMO company in the area of drug discovery, development and commercialization.
About Shuttle Pharmaceuticals
Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharmaceuticals is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination with surgery, chemotherapy and immunotherapy. For more information, please visit our website at www.shuttlepharma.com.
About Boustead Securities, LLC
Boustead Securities, LLC is an investment banking firm that executes and advises on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions, for a broad client base. Boustead’s core value proposition is the ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States, Boustead’s team moves quickly and provides a broad spectrum of sophisticated financial advice and services. Boustead is a majority-owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. For more information visit please visit: www.boustead1828.com